No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine-Reference-Cited by-同舟云学术

No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine

Published:2015-10-01 Issue:6 Volume:2 Page:e158
ISSN:2332-7812
Container-title:Neurology - Neuroimmunology Neuroinflammation
language:en
Short-container-title:Neurol Neuroimmunol Neuroinflamm

Author:

Pakpoor Julia,Disanto Giulio,Altmann Daniel R.,Pavitt Sue,Turner Benjamin P.,Marta Monica,Juliusson Gunnar,Baker David,Chataway Jeremy,Schmierer Klaus

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Neurology (clinical),Neurology

Reference23 articles.

1. Multiple sclerosis

2. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes

3. A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

4. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

5. Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis

Cited by 115 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. [Translated article] Risk of Skin Cancer Associated with Disease-Modifying Therapies in Multiple Sclerosis: A Comprehensive Evidence Review;Actas Dermo-Sifiliográficas;2024-09

2. Riesgo de cáncer cutáneo asociado a terapias modificadoras de la enfermedad en la esclerosis múltiple: revisión narrativa de la evidencia actual;Actas Dermo-Sifiliográficas;2024-09

3. Making Information About Cladribine Tablets Accessible to People with Multiple Sclerosis: A Patient-Survey-Led Narrative Review for Healthcare Professionals;Neurology and Therapy;2024-05-17

4. Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society;Multiple Sclerosis Journal;2024-02-15

5. Health, Wellness, and the Effect of Comorbidities on the Multiple Sclerosis Disease Course;Neurologic Clinics;2024-02